Cargando…

Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot

In recent years we and others have used the ELISPOT assay successfully to identify novel tumor antigens by the characterization of spontaneous HLA class I restricted immune responses against a number of minimal 9–10 amino acid long peptide epitopes. In the present study, we examined the capability o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larsen, Stine Kiaer, Hansen, Morten, Svane, Inge Marie, Straten, Per Thor, Andersen, Mads Hald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901095/ https://www.ncbi.nlm.nih.gov/pubmed/24710413 http://dx.doi.org/10.3390/cells1020051

Ejemplares similares

Natural CD4(+) T-Cell Responses against Indoleamine 2,3-Dioxygenase
por: Munir, Shamaila, et al.
Publicado: (2012)

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens
por: thor Straten, Per, et al.
Publicado: (2010)

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application
por: Junker, Niels, et al.
Publicado: (2011)

Therapeutic Cancer Vaccines in Combination with Conventional Therapy
por: Andersen, Mads Hald, et al.
Publicado: (2010)

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes
por: Donia, Marco, et al.
Publicado: (2012)

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors
por: Andersen, Rikke Sick, et al.
Publicado: (2010)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

A Potential Role of Indoleamine 2,3-Dioxygenase–Specific T cells in Leishmania Vaccination
por: Straten, Per thor, et al.
Publicado: (2011)

Cancer treatment: the combination of vaccination with other therapies
por: Andersen, Mads Hald, et al.
Publicado: (2008)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
por: Donia, Marco, et al.
Publicado: (2012)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes
por: Køllgaard, Tania, et al.
Publicado: (2015)

Characterization of T-cell responses against IκBα in cancer patients
por: Munir, Shamaila, et al.
Publicado: (2012)

T-cell clonotypes in cancer
por: thor Straten, Per, et al.
Publicado: (2004)

Inflammation induced PD-L1-specific T cells
por: Munir, Shamaila, et al.
Publicado: (2019)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
por: Andersen, Mads Hald, et al.
Publicado: (2006)

The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
por: Sørensen, Rikke Bæk, et al.
Publicado: (2009)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

Exploitation of gamma delta T cells in cancer immunotherapy as combined antigen-presenters and cancer cell killers
por: Holmen Olofsson, Gitte, et al.
Publicado: (2014)

First in man study: Bcl-Xl_42-CAF(®)09b vaccines in patients with locally advanced prostate cancer
por: Mørk, Sofie Kirial, et al.
Publicado: (2023)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses
por: Køllgaard, Tania, et al.
Publicado: (2012)

Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an HLA-A2-restricted epitope derived from indoleamine 2,3 dioxygenase
por: Iversen, Trine Z, et al.
Publicado: (2013)

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2018)

Modified ELISPOT: Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials
por: Malyguine, Anatoli
Publicado: (2005)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2020)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

The Structural Biology of Bcl-x(L)
por: Lee, Erinna F., et al.
Publicado: (2019)

Rational design of Harakiri (HRK)-derived constrained peptides as BCL-x(L) inhibitors
por: Zhang, Peiyu, et al.
Publicado: (2023)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
por: Handlos Grauslund, Jacob, et al.
Publicado: (2021)

Response definition criteria for ELISPOT assays revisited
por: Moodie, Z., et al.
Publicado: (2010)

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients
por: Iversen, Trine Zeeberg, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_u9m4cjmjtrcgh2r9opcbplp9c6